{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:27:52Z","timestamp":1784798872186,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Clin. Diabetes Healthc."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Obesity in pediatric patients is strongly associated with increased vascular and metabolic risk. Prediabetes is present in up to 1 in 5 adolescents, aged 12-18 years-old, though is thought to remit spontaneously in a significant portion. Pediatric patients with type 2 diabetes mellitus (T2D) have a more rapid decline of beta-cell function and progression to treatment failure than adult T2D patients. Thus, there is a strong interest in better understanding the natural history of prediabetes in these youth. We aimed to evaluate the real-world rate of progression of prediabetes to T2D in adolescent patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective study of 9,275 adolescent subjects aged 12-21 years-old with at least 3 years of de-identified commercial claims data and a new diagnosis of prediabetes during the observation period. Enrollees with a T2D diagnosis and\/or diabetes medication use in the 1 year prior to prediabetes diagnosis or a T2D diagnosis in the 1 month following prediabetes diagnosis were excluded. Enrollees with diagnoses of type 1 diabetes (T1D) or polycystic ovarian syndrome over the 3 years were also excluded. Progression to T2D was defined by claims data of two T2D diagnoses at least 7 days apart, HbA1c \u2265  6.5%, and\/or prescription of insulin without known T1D. Enrollees were followed for 2 years after prediabetes diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 232 subjects (2.5%) progressed from prediabetes to T2D. There were no differences found in T2D progression based on sex or age. Progression to T2D occurred at a median of 302 days after prediabetes diagnosis (IQR 123 to 518 days). This study was limited by the lack of laboratory\/anthropometric data in administrative claims, as well as the exclusion of 23,825 enrollees for lack of continuous commercial claims data over 3 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In the largest sample to date on adolescent prediabetes, we found a 2.5% progression of prediabetes to T2D over a median duration of about one year.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcdhc.2023.1181729","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T05:24:52Z","timestamp":1683609892000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Progression from prediabetes to type 2 diabetes mellitus in adolescents: a real world experience"],"prefix":"10.3389","volume":"4","author":[{"given":"Alyson","family":"Weiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Tchang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Gandica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Murillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.6361","article-title":"Trends in obesity prevalence among children and adolescents in the united states, 1988-1994 through 2013-2014","volume":"315","author":"Ogden","year":"2016","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-3459","article-title":"Prevalence of obesity and severe obesity in US children, 1999-2016","volume":"141","author":"Skinner","year":"2018","journal-title":"Pediatrics"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2019.4498","article-title":"Prevalence of prediabetes among adolescents and young adults in the united states, 2005-2016","volume":"174","author":"Andes","year":"2020","journal-title":"JAMA Pediatr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.3.638","article-title":"Youth type 2 diabetes: insulin resistance, beta-cell failure, or both","volume":"28","author":"Gungor","year":"2005","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1642","article-title":"Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline","volume":"96","author":"Copeland","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5448.2012.00915.x","article-title":"Progressive deterioration of beta-cell function in obese youth with type 2 diabetes","volume":"14","author":"Bacha","year":"2013","journal-title":"Pediatr Diabetes"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5448.2011.00841.x","article-title":"Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study","volume":"13","author":"Bacha","year":"2012","journal-title":"Pediatr Diabetes"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-014-0508-y","article-title":"Obesity and type 2 diabetes in children: epidemiology and treatment","volume":"14","author":"Pulgaron","year":"2014","journal-title":"Curr Diabetes Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4274\/jcrpe.2017.S005","article-title":"Insulin resistance, prediabetes, metabolic syndrome: what should every pediatrician know","volume":"9","author":"Ighbariya","year":"2017","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1263150","article-title":"Impaired glucose tolerance in obese white children and adolescents: three to five year follow-up in untreated patients","volume":"119","author":"Kleber","year":"2011","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.4.902","article-title":"Predictors of changes in glucose tolerance status in obese youth","volume":"28","author":"Weiss","year":"2005","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/pedi.12570","article-title":"Longitudinal follow up of dysglycemia in overweight and obese pediatric patients","volume":"19","author":"Love-Osborne","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(18)30235-9","article-title":"Trajectories of changes in glucose tolerance in a multiethnic cohort of obese youths: an observational prospective analysis","volume":"2","author":"Galderisi","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study","volume":"374","author":"Knowler","year":"2009","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(17)30044-5","article-title":"Prediabetes in youth - mechanisms and biomarkers","volume":"1","author":"Weiss","year":"2017","journal-title":"Lancet Child Adolesc Health"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S003","article-title":"Prevention or delay of type 2 diabetes and associated comorbidities: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0416-8","article-title":"Therapeutic use of metformin in prediabetes and diabetes prevention","volume":"75","author":"Hostalek","year":"2015","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/pedi.12719","article-title":"ISPAD clinical practice consensus guidelines 2018: type 2 diabetes mellitus in youth","author":"Zeitler","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12379","article-title":"Metformin prescription patterns among US adolescents aged 10-19 years: 2009-2013","volume":"41","author":"Wang","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4251","article-title":"Optimal macronutrient content of the diet for adolescents with prediabetes; RESIST a randomised control trial","volume":"98","author":"Garnett","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41387-018-0057-6","article-title":"Long-term metformin treatment in adolescents with obesity and insulin resistance, results of an open label extension study","volume":"8","author":"Lentferink","year":"2018","journal-title":"Nutr Diabetes"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e14249","DOI":"10.1097\/MD.0000000000014249","article-title":"The effects of metformin on insulin resistance in overweight or obese children and adolescents: a PRISMA-compliant systematic review and meta-analysis of randomized controlled trials","volume":"98","author":"Sun","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2710","article-title":"Metformin in obese children and adolescents: the MOCA trial","volume":"98","author":"Kendall","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0787","article-title":"Impact of insulin and metformin versus metformin alone on beta-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes","volume":"41","author":"Consortium","year":"2018","journal-title":"Diabetes Care"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13232","article-title":"Real-world treatment escalation from metformin monotherapy in youth-onset type 2 diabetes mellitus: a retrospective cohort study","volume":"22","author":"Vajravelu","year":"2021","journal-title":"Pediatr Diabetes"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021","volume":"44","author":"American Diabetes","year":"2021","journal-title":"Diabetes Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/pedi.13206","article-title":"Development of type 2 diabetes in adolescent girls with polycystic ovary syndrome and obesity","volume":"22","author":"Hudnut-Beumler","year":"2021","journal-title":"Pediatr Diabetes"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-022-07412-9","article-title":"Clinical care among individuals with prediabetes in primary care: a retrospective cohort study","volume":"37","author":"Tseng","year":"2022","journal-title":"J Gen Intern Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-s215","article-title":"Treatment of type 2 diabetes in youth","author":"Flint","year":"2011","journal-title":"Diabetes Care"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.14543","article-title":"Screening for prediabetes and type 2 diabetes in children and adolescents: US preventive services task force recommendation statement","volume":"328","author":"Mangione","year":"2022","journal-title":"JAMA"}],"container-title":["Frontiers in Clinical Diabetes and Healthcare"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2023.1181729\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T05:24:55Z","timestamp":1683609895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2023.1181729\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":30,"alternative-id":["10.3389\/fcdhc.2023.1181729"],"URL":"https:\/\/doi.org\/10.3389\/fcdhc.2023.1181729","relation":{},"ISSN":["2673-6616"],"issn-type":[{"value":"2673-6616","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"article-number":"1181729"}}